In this multicenter study (ISS 902), 554 previously untreated patients with <500 CD4 cells! mnr' and mildly symptomatic human immunodeficiency virus disease were randomized to receive zidovudine or didanosine (ddI). After a mean follow-up of 20 months, 80 patients (40 zidovudine, 40 ddI) had died and 146 had at least one AIDS-defining event (73 zidovudine, 73 ddI). Overall, no difference was found between treatments with respect to progression to AIDS or death. The analysis of relative risk (RR) of progression over time, however, showed an initially minor risk for zidovudine patients and an inversion in the zidovudine-ddI RR in the second and third years of follow-up. Didanosine showed a greater effect on CD4 cell count response. The two drugs confirmed the toxicity patterns already reported in other trials, with a low occurrence of pancreatitis (ddI 1.3%, zidovudine 0.4%). The overall results suggest that, in this population, zidovudine and ddI monotherapies have comparable long-term clinical efficacy and that more powerful regimens should be preferred.
In this multicenter study (ISS 902), 554 previously untreated patients with <500 CD4 cells! mnr' and mildly symptomatic human immunodeficiency virus disease were randomized to receive zidovudine or didanosine (ddI). After a mean follow-up of 20 months, 80 patients (40 zidovudine, 40 ddI) had died and 146 had at least one AIDS-defining event (73 zidovudine, 73 ddI). Overall, no difference was found between treatments with respect to progression to AIDS or death. The analysis of relative risk (RR) of progression over time, however, showed an initially minor risk for zidovudine patients and an inversion in the zidovudine-ddI RR in the second and third years of follow-up. Didanosine showed a greater effect on CD4 cell count response. The two drugs confirmed the toxicity patterns already reported in other trials, with a low occurrence of pancreatitis (ddI 1.3%, zidovudine 0.4%). The overall results suggest that, in this population, zidovudine and ddI monotherapies have comparable long-term clinical efficacy and that more powerful regimens should be preferred.
Zidovudine has been the most widely used nucleoside analogue in first-line treatment of human immunodeficiency virus (HIV) infection. Although zidovudine monotherapy proved effective in prolonging survival in untreated patients with advanced HIV infection [1] [2] [3] , several observations have shown that the clinical benefit of zidovudine monotherapy has a limited duration [4] [5] [6] [7] [8] [9] , with the emergence of drug-resistant HIV variants representing one possible factor involved [10] .
Didanosine (ddI) is another available nucleoside analogue, which is characterized, compared with zidovudine, by a different pattern of toxicity [11] and a different genetic resistance pattern [10] and by a phosphorylation profile suggesting more pronounced in vitro activity on particular cell populations, such as "resting" cells [12] . In phase I studies, peripheral neuropathy and pancreatitis were the main ddI-associated dose-limiting toxicities, with a lower hematologic toxicity rate compared with zidovudine.
Two major studies have compared ddI and zidovudine in patients with no or little experience with zidovudine [13, 14] . The AIDS Clinical Trials Group (ACTG) 1I6A study evaluated patients with < 16 weeks of zidovudine treatment; these patients had AIDS-related complex (ARC) or AIDS and <300 CD4 cells/nun' or were asymptomatic with <200 CD4 cells/ mnr'. That study showed overall no differences between zidovudine and ddI but indicated a better efficacy of zidovudine in naive patients in preventing progression to a new AIDS-defining event or death [13] . Results from the ACTG 175 trial, evaluating patients with 200-500 CD4 cells/mnr', were different, indicating in previously untreated patients a greater efficacy of ddI in preventing AIDS, death, or a CD4 cell decline >50%; however, the difference was no longer significant when evaluating clinical end points only (new AIDS-defining events or death) [14] . The comparative efficacy ofzidovudine and ddI in antiretroviral-naive patients is therefore still controversial. Furthermore, any comparison between these two trials must take into account the different CD4 cell range of the populations studied.
Our study is another large phase III trial designed to investigate the clinical efficacy and toxicity of zidovudine and ddI as first-line treatments. In contrast to the two previous trials, however, this trial evaluated a population entirely composed of patients with ARC and characterized, with respect to CD4 cells, by a wide inclusion range «500/mm 3 ) , which overlaps the cumulative CD4 cell range of the other two major trials mentioned above.
Methods
Study population. Eligible subjects were HIV-positive patients with ARC (CDC 1987 definition) and without any previous antiretroviral treatment. The 1987 CDC definition of AIDS was maintained throughout the study both for inclusion into the trial and for the definition of clinical end points (first AIDS-defining events, which included Kaposi's sarcoma).
Other main eligibility criteria were a hemoglobin concentration of ;::90 giL, a total neutrophil count of ;::10 9/L, a platelet count of ;::25 X 10 9 IL, serum transaminase levels no higher than 6 times the upper limit of normal, serum amylase values within 1.25 times the upper limit of normal, age > 16 years, and a Kamofsky index value >80.
The main exclusion criteria were previous treatment with other antiretroviral drugs, pregnancy or lactation, severe diarrhea unresponsive to treatment, a history of or current pancreatitis, bilateral moderate peripheral neuropathy, the need for neurotoxic or cytotoxic therapies, and transfusions in the 30 days preceding randomization.
Allowable concomitant treatments included maintenance therapy of AIDS-defining opportunistic infections and cotrimoxazole or aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis. The use of other antiretroviral drugs, systemic corticosteroids, or experimental drugs was not allowed. The patients were recruited from 37 infectious diseases hospital divisions or university-affiliated medical centers. The coordinating center responsible for randomization, data collection, monitoring, and analysis was the Laboratory of Virology, Istituto Superiore di Sanita (ISS)
Study design, efficacy measures, and treatment regimens. The study was an open-label, centrally randomized trial. Patients were randomly assigned to receive either zidovudine or ddI according to a randomized block design by clinical center and body weight «60 or ;::60 kg). Primary efficacy end point was time to a first AIDS-defining event or death, analyzed by the intent-to-treat approach. Clinical end points were reviewed by trial monitors of the coordinating center. Secondary efficacy analysis included survival and changes during treatment in CD4 cell count, p24 antigenemia, body weight, and Kamofsky score. Patient recruitment started in September 1990 and was stopped in July 1993, after randomization of 573 patients.
The assigned dosage of zidovudine (Wellcome, Beckenham, UK) was 12 mg/kg/day (range, 500-:-1000 mg). ddI (Bristol-Myers Squibb, Wallingford, CT) was assigned on a weight-adjusted basis; a 375-or 250-mg sachet was given twice daily to patients weighing ;::60 or <60 kg, respectively.
Toxicity management. The definitive discontinuation of treatment was recommended under one or more of the following conditions: (1) any life-threatening or grade 4 toxicity event, (2) recurrences of grade 3 toxicity events, (3) signs and symptoms suggestive of pancreatitis, (4) increase in triglycerides >750 mg/dL, or (5) severe treatment-related peripheral neuropathy or recurrence of peripheral neuropathy grade 2. Severe peripheral neuropathy was defined by severe discomfort, presence of paresthesias, or pain requiring narcotic analgesia.
Evaluation ofpatients. Pretreatment evaluation included a medical history; a physical examination, including neurologic evaluation; evaluation of HIV-related signs and symptoms; and determination of body weight, temperature, Kamofsky score, and laboratory measures. The lymphocyte phenotyping of peripheral blood mononuclear cells and the determination of p24 antigenemia in serum, using licensed test kits, were done in one laboratory at each center.
All patients were evaluated at 2 and 4 weeks after enrollment and every 4 weeks thereafter. Patients who withdrew from the study after randomization but before enrollment and patients who later discontinued therapy were subsequently followed for first AIDS-defining events and survival. AIDS-defining events and survival were cross-checked using the Italian National AIDS Registry, based at the ISS, Centro Operativo AIDS, Rome.
Statistical analysis. The Kaplan-Meier method was used to analyze times to a first AIDS-defining event or death and survival. The log-rank or Wilcoxon test, as appropriate, was used for comparison of risks of primary and secondary end points between treatment groups. The Cox proportional hazards model was used to estimate both the adjusted and unadjusted relative risks (RRs) of ddI and zidovudine. In cases of nonproportional risks over time, linear and quadratic effects on annual change in the ddI-zidovudine log RR were included in the Cox model.
Mean changes from baseline in CD4 cell count and body weight and mean Kamofsky values were calculated monthly for patients being treated and compared at 1,6, 12, and 18 months after enrollment, using the Wilcoxon nonparametric two-sample test. All P values were two-sided and not adjusted for multiple testing.
Assuming 15% progression to AIDS or death for zidovudinetreated patients at 18 months, 102 primary events were necessary to detect for ddI at 18 months an absolute 6% lower progression or a 10% higher progression (9% and 25% progression, respectively), with a power of 80% and a two-sided significance level of .05 using the log-rank test [15] . Assuming a constant RR over the whole observation period and a mean observation time of 18 months, the calculated sample size was 284 patients per treatment arm.
Primary efficacy analysis was based on a time-to-event, intentto-treat approach, with a cutoff date of 28 February 1994. Time to AIDS or death and survival were also analyzed for enrolled patients considering, in two separate analyses, that all events and only events occurred while the patient was being treated or within 30 days from definitive treatment discontinuation. Toxicity analy- There were 573 patients randomized between September 1990 and July 1993. Nineteen (10 ddl, 9 zidovudine) were excluded from the analysis as not eligible for the following reasons: ARC symptoms not confirmed according to predetermined criteria (12 patients, 6 zidovudine, 6 ddl), established diagnosis of AIDS (6 patients, 3 zidovudine, 3 ddI), CD4 cell counts repeatedly > 500 mnr' (1 patient, zidovudine). The remaining 554 randomized patients were considered for analysis. They consisted of 396 male (71%) and 158 female patients (29%), with a mean age of32 years and a mean CD4 cell count of 234/mm 3 (table 1) . Sixty-eight patients (36 zidovudine, 32 ddl) were withdrawn from the study between randomization and enrollment for the following reasons: HIV-related death or development of a first AIDS-defining event (5 zidovudine, 9 ddl), loss to follow-up after randomization (12 zidovudine, 7 ddl), grade I-II adverse events or abnormalities in laboratory values (3 zidovudine, 3 ddl), clinical deterioration (1 zidovudine), use of drugs or incompatible therapies (2 ddl), patient's request for unspecified personal reasons (11 zidovudine, 8 ddl) , and noncompliance with protocol requirements (4 zidovudine, 3 ddl). These patients were followed for the first AIDS-defining event and survival and included in the primary efficacy analysis, according to the intent-to-treat approach.
The 486 patients enrolled (239 zidovudine, 247 ddl) included 18 patients (7 zidovudine, 11 ddl) with minor violations of inclusion criteria: 2 (1 zidovudine, 1 ddl) with only one CD4 cell count <500/mm 3 , 6 (3 zidovudine, 3 ddl) with a Kamofsky score of 70 (including 1 patient in the ddl arm who also had transaminase levels >6 times the upper limit of normal), 1 (ddl) with < 1000 granulocytes/mnr', and 9 (3 zidovudine, 6 ddl) with serum amylase levels > 1.25 times the upper limit of normal.
Treatment groups were similar with respect to ARC-defining conditions, Kamofsky score, sex, age, CD4 cell count, PCP prophylaxis, p24 antigenemia, hematologic values, and route of HIV transmission (table 1) .
Patient Sample
Results ses were also done for enrolled patients only; the censoring time was 30 days after definitive drug discontinuation.
At the completion of the study, the actual power of the study was recalculatedaccordingto the number of observedprimary end points (158 AIDS events or deaths)and to the observed zidovudine cumulative probabilityof progressionor death at 18 months (20%), assuming a ddl-zidovudine RR constant over time: At the same levels of a (0.05) and /3 (0.20), the number of observed events was adequate to detect an RR of primary end point between treatments of at least 1.57, corresponding to a -10% (ddI) or +7% (zidovudine) difference at 18 months in AIDS-free survival.
All statisticalanalyses were made using the SAS statisticalpackage (SAS, Cary, NC). JID 1997; 175 (February) or cutoff) was 13.6 months (range, 1 day to 39.1 months) for the zidovudine group (58.8% of the total follow-up time) and 13.4 months (range, 1 day to 40.4 months) for the ddI group (61.3% of the total follow-up time). The proportion of time spent receiving full study dosage versus time receiving treatment (defined above) was 76.3% in the zidovudine group and 83.8% in the ddI group. The proportion of time spent receiving a reduced dose (defined by a reduction of at least 200 mg of the original dose) versus time receiving treatment was 20.5% in the zidovudine group and 13.0% in the didanosine group.
Drug modifications (permanent discontinuation or dose reduction, defined above) occurred very frequently (428/486 patients enrolled). The analyses oftime to permanent discontinuation of treatment and of time to first dose modification showed no differences between the 2 treatment groups (log-rank, P = .84 and P = .99, respectively).
Primary Clinical End Point: Evolution to AIDS or Death 14 ddI, 1 death); 56 events occurred in patients receiving treatment or within 30 days after definitive discontinuation (24 zidovudine; 32 ddI, 5 deaths); 76 events (44 zidovudine, 13 deaths; 32 ddI, 4 deaths) occurred >30 days after definitive treatment discontinuation.
Rates of disease progression or deaths per 100 person-years for the 2 treatment groups, for the whole observation period and for each study year, are reported in table 4.
Kaplan-Meier estimates of time to the first AIDS-defining event or death since randomization per treatment group are shown in figure 1. The estimated probabilities of being alive and AIDS-free at 12, 18, and 24 months (±SE) were, respectively, 86.8% (±2.2), 80.0% (±2.7), and 67.3% (±3.4) for the zidovudine group and 80.0% (±2.5), 72.4% (±2.9), and 69.8% (±3.1) for the ddI group. Twenty-five percent of patients developed AIDS or died within an estimated 19.4 months from randomization in the zidovudine group and within an estimated 16.0 months in the ddI group.
The unadjusted estimate of ddI-zidovudine RR of disease progression or death, calculated in a proportional hazards model on all randomized eligible patients, was 0.95 (95% confidence interval [CI], 0.70-1.30; log-rank, P = .75; Wilcoxon, P = .42), suggesting no differences between effects ofzidovudine and ddI. The above analysis of risk ofprogression, however, assumes constant risk over time. In our study, annual rates showed a different trend in risk over time for the 2 treatment groups (table 4), increasing for zidovudine and decreasing for ddI. When a linear effect on the ddI-zidovudine log RR over time was included, a Cox model indicated an annual change in RR represented by a multiplicative factor of 0.5 (95% CI, 0.32-0.78; P = .002) with a ddI-zidovudine RR of 1.45 (95% CI, 0.96-2.19) in the first year. The ddI-zidovudine RR appeared to be constant over time during the first 18 months after randomization. The estimate of the unadjusted ddI-zidovudine Table 3 . Observation time for primary end point (new AIDS-defining event or death).
Person-years (%)
Zidovudine ddI * From enrollment to permanent discontinuation or cutoff.
Observation time preceding AIDS, death, or last information was 413 person-years in the zidovudine group and 425 personyears in the ddI group. The proportion of this time spent receiving assigned treatment, no treatment, or the opposite treatment is shown in table 3.
Among the 554 randomized eligible patients, at the cutoff date, 134 had at least one AIDS-defining event (66 zidovudine, 68 ddI), 12 died of a first AIDS defining event (7 zidovudine, 5 ddI), and 12 died before progressing to AIDS (7 zidovudine, 5 ddI).
With respect to treatment status, 27 AIDS-defining events occurred before the start of treatment (13 zidovudine RR for this period was 1.45 (95% CI, 0.99-2.11; log-rank, P = .051; Wilcoxon, P = .053), suggesting a trend for a better efficacy of zidovudine in this period. No major differences were observed between treatment groups with respect to diseases defining progression to AIDS or causes of death before progression to AIDS (table 5) .
The primary end points from the start of treatment were also analyzed to control for possible treatment differences among the patients who actually started the assigned treatment. These analyses, under the assumption of constancy of RR over time, as for the intent-to-treat analysis, showed similar crude risks for the 2 treatment groups, with a ddI-zidovudine RR of disease progression or death of 0.92 (95% CI, 0.65-1.29; log-rank, P = .62; Wilcoxon, P = .71). For the above analysis, however, the ddl-zidovudine RR was not constant over time (test on linear change of the log RR, P = .033).
Finally, disease progression was analyzed using only the time receiving treatment or within 30 days after definitive dis- continuation to evaluate the "on treatment" efficacy. Under the assumption of proportional risks, the estimate of the ddIzidovudine RR was 1.28 (95% CI, 0.78-2.13) for the whole period and 1.60 (95% CI, 0.91-2.80) for the first 18 months from enrollment, in accordance with the trend for an initially greater efficacy of zidovudine observed in the other analyses.
With adjustment for baseline CD4 cell counts (~200 or >200/mm 3 ) , almost unchanged ddI-zidovudine RRs were observed in all the analyses reported above, confirming that the 2 treatment groups were well balanced with respect to baseline CD4 cell counts. The interaction between CD4 cell count and treatment was also studied to evaluate possible differences of ddI-zidovudine relative efficacy according to baseline CD4 cell counts. Although no significant interaction was found, a trend '" Cl.l No differences were observed between the 2 treatment groups in terms of p24 antigen-negative patients who became p24 antigen-positive in at least one follow-up evaluation (32/146 zidovudine, 29/154 ddI; log-rank, P = .51).
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CD4 cell response. Baseline CD4 cell counts were available for all patients. CD4 cell counts were collected monthly until definitive drug discontinuation. Analysis of mean absolute change from baseline values over time showed a greater increase from baseline in ddI-treated patients (figure 3), significant at 1 and 6 months (nonparametric Wilcoxon, unadjusted for multiplicity, P = .032 and P = .017, respectively). In comparing median changes from baseline, ddI was still better than zidovudine but not significantly. To further investigate this phenomenon, we evaluated CD4 cell count changes according to baseline (~200 or > 200 CD4 cells/nun").In patients with > 200 CD4 cells/mnr' at baseline, the effect of ddI on mean and median CD4 cell changes was constantly better than that of zidovudine at all time points. Conversely, among patients with~200 CD4 cells/mrrr' at baseline, an irregular trend was observed, with no clear superiority of either treatment. CD4 cell changes at 1, 6, 12, and 18 months after enrollment are shown in table 6 .
Body weight, Karnofsky score, and indirect measures of compliance. Monthly assessments of body weight (mean absolute changes from baseline) and Karnofsky score showed very similar trends over time in both treatment groups (data not shown).
Longitudinal data on mean corpuscular volume and serum uric acid, collected until definitive treatment discontinuation, showed clearly distinct patterns for the zidovudine and ddI treatment arms. This was in accordance with the time spent 
Survival
At the cutoff date, 69 patients had died of HIV-related events or AIDS (34 zidovudine, 35 ddI). Five patients died of non-HIV-related events (2 zidovudine, 3 ddI), and 6 patients died due to unknown reasons (4 zidovudine, 2 ddI).
Kaplan-Meier estimates of survival time since randomization to treatment group are shown in figure 2. The estimated probabilities of being alive at 12, 18, and 24 months (±SE) were, respectively, 96.2% (±1.2%), 92.3% (±1.8%), and 86.0% (±2.6%) for the zidovudine group and 92.6% (± 1.7%),88.6% (±2.1%), and 82.8% (±2.7%) for the ddI group. Twenty-five percent of patients were estimated to die within 33.5 months after randomization in the zidovudine group and within 41.1 months in the ddI group.
The unadjusted estimate of ddI-zidovudine RR of death, calculated in a proportional hazards model, was 1.01 (95% CI, 0.65-1.57) for the whole period and 1.55 (95% CI, 0.84-2.86) for the first 18 months from randomization. Estimates were unchanged with adjustment for baseline CD4 cell count. No differences were observed between. treatment groups in the causes of death (data not shown). In both subgroups, however, as for the whole population, the assumption of a constant ddI-zidovudine RR over time was not satisfied. The initial ddI-zidovudine RR and its annual change were even greater in patients with > 200 CD4 cells/ mrrr' with respect to the whole population ( relative efficacy of the two treatments in completely zidovudine-naive patients but with controversial results. Among the 380 subjects in the ACTG 116A study with no prior zidovudine treatment, zidovudine was more effective than 750 mg/day ddI in terms of progression to AIDS or death. There was a similar trend, although not significant, in the comparison of zidovudine with ddI at 500 mg/day. That study evaluated patients with ARC or AIDS and <300 CD4 cells/mnr' or asymptomatic patients with <200 CD4 cells/mrrr' [13] . The ACTG 175 trial, although mainly designed to evaluate the possible benefit of combination therapy over monotherapy, also provided information on the comparison between zidovudine and ddI in both pretreated and untreated patients with a CD4 cell count of 200-500/mm 3. Among zidovudine-naive subjects, ddI (400 mg/day) was more effective than zidovudine Log-rank test, P ddI-zidovudine
No. of events Discussion receiving the full or reduced dose, suggesting good compliance with treatment assigned (data not shown).
Adverse events. The number of patients withdrawn from assigned treatment because of adverse events was higher in the ddI group (48 ddI, 34 zidovudine). Among the reasons for discontinuation of treatment, some adverse events were treatment-specific, such as hyperamylasemia, which was in part responsible for the higher number of discontinuations in the ddI group. Eighteen patients (6 zidovudine, 12 ddI) had baseline laboratory values corresponding to a grade 3-4 toxicity and 7 patients (2 zidovudine, 5 ddI) had abnormal baseline values of amylase and were excluded from the analyses evaluating the onset of these specific toxicities after baseline. Eighty-nine zidovudine patients and 95 ddI patients had at least one new grade 3-4 (if pancreatic, any grade) treatment-related (at least possibly) adverse event while receiving treatment or within 30 days after treatment discontinuation. The risk of a new severe toxicity (defined above) appeared to be comparable between the 2 treatment groups (ddI-zidovudine RR, 1.1; 95% CI, 0.8-1.4; log-rank, P = .72), with no significant interaction between baseline CD4 cell count (>200 or~200/mm3) and treatment (data not shown). Severe adverse events by body system and treatment arm are reported in table 7 together with, where appropriate, ddI-zidovudine RR estimates.
Some controlled trials have compared zidovudine and ddI in both zidovudine-naive and zidovudine-experienced subjects [13, 14, [16] [17] [18] . The results of those trials overall suggest that the relative efficacy of zidovudine and ddI can vary according to the extent ofprevious experience with zidovudine; switching to ddI is generally more effective than continuing zidovudine after a few weeks or months of zidovudine monotherapy [16] [17] [18] . Two of these trials have also provided information on the in preventing AIDS, death, or a > 50% decline in CD4 cell count, with a similar but not significant trend considering clinical end points only (new AIDS-defining events or death) [14] . Although the two trials gave apparently conflicting results, a direct comparison may not be appropriate because of the different ranges in CD4 cell count of the two populations and of the different ddI dosages used. The population of our trial, having a wide range of CD4 cell counts « 500/mm 3 ) , allows some comparison with both the above trials.
In the present trial, when considering the primary study end points (development of a new AIDS event or death), the number of events at the end of the study was similar in the 2 treatment groups. However, the end-point distribution over time was characterized by a significant and progressive change in the ddI-zidovudine RR of end point over time; zidovudine was more effective in the first 18 months, and there was a lower risk of end point for ddI-assigned subjects after 18 months ( figure 1, table 4 ). The same phenomenon was also observed considering survival only (figure 2).
Although it is difficult to explain the possible bases of this trend, which probably is dependent on a complex interplay of several factors, some considerations can be made. First, it is possible that the relative efficacy of the two drugs can vary according to the baseline CD4 cell count of the patients, with zidovudine more effective in more patients with more advanced HIV disease and ddI more effective in less immunocompromised patients. However, this hypothesis, which is compatible with the results of the ACTG 116A and 175 studies, is not supported in our trial by a subgroup analysis ofclinical efficacy, which showed no significant interaction between treatment group and CD4 cell baseline levels (~200 or > 200/mm 3 ) .
Conversely, in favor of the hypothesis is the subgroup analysis of CD4 cell response, which indicates, among patients with > 200 CD4 cells/mnr', a better response to treatment in ddItreated patients. On the basis of our data, we can therefore conclude that a differential efficacy of the two drugs according to CD4 cell baseline levels was suggested mainly by data of immunologic response to treatment. The reasons for and the meaning of this possible differential activity of the two drugs are uncertain. Zidovudine and ddI are characterized by different phosphorylation profiles, which suggest differential activity in resting and activated T cells [12] . On the basis of this observation, it is possible that the composition of the T cell compartment, with respect to these two cellular populations, can vary according to several factors, including the level of peripheral CD4 cells. It is also possible that a different resting/activating cell profile could be responsible for different responses in terms of magnitude and duration of clinical efficacy, according to the nucleoside used. Further studies are necessary to test this hypothesis.
It is remarkable that, in our study, a dissociation between the clinical and immunologic effects of treatment was observed for the two drugs; ddI continuously was more effective than zidovudine as determined by numbers of CD4 cells during the course of the study. Differences in CD4 cell response, although involving a "surrogate" marker that explains only part of clinical response, may influence subsequent clinical progression. In our trial, the better effect of ddI on CD4 cell count, particularly in patients with > 200 CD4 cells/mnr', might have translated into a more favorable clinical benefit later in the study, explaining in part the better long-term outcome for subjects receiving ddI.
Other biologic reasons may also be responsible for the particular trend observed. Differences between the two drugs in terms of timing and degree of drug resistance have been reported, with earlier development of resistance to zidovudine than to ddI [19] . Although drug resistance can only partially explain the loss of efficacy of treatment over time, this phenomenon could have a role in the observed trend. Unfortunately, the number of virologic samples collected in our study did not allow the evaluation of resistance or the quantitation of virus load, which could have been helpful in testing this hypothesis and in assessing more precisely the antiviral activity of the two drugs.
From a methodologic point of view, although zidovudine and ddI proved to be comparable options in the long term, conclusions on the clinical effect of trial treatments during the second and third years of follow-up could have been influenced by the intent-to-treat approach used in our trial. This approach includes in the analysis the end points following the discontinuation of treatment. We cannot exclude the possibility that the trend for a better late outcome for ddI-treated subjects could be in part dependent on events or factors subsequent to the discontinuation of treatment. However, observation of the same trend in the analysis of the trial through an "on treatment" approach indicates that this phenomenon is not produced by the intent-to-treat analysis. Furthermore, the evaluation of possible differences in follow-up after discontinuation of treatment showed no major differences between the 2 treatment groups in terms oftime between discontinuation of treatment and clinical end point, trial termination, or loss to follow-up.
The intent-to-treat approach by randomization and the relatively high number of patients who were lost to follow-up or who discontinued treatment before reaching an end point may have potentially limited the capacity of our study to detect differences between treatments. That all randomized subjects would be included in the main analysis was decided before the study. Although this approach may dilute efficacy differences between treatments, it is generally considered an appropriate and necessary tool to ensure balance among treatment groups and counteract possible sources of bias (e.g., the effect of drug assignment on whether patients in open trials discontinued treatment). In our study, the patients who withdrew from the study between randomization and enrollment were comparable by treatment group by number, sex, and CD4 cell count. To exclude a possible different direction of the results among enrolled patients, the trial was also analyzed considering only the subjects who started treatment, and the two analyses provided essentially identical results.
The relatively high proportion of discontinuations and losses to follow-up, which are common limitations of longterm clinical studies, may have been enhanced in our trial by the high proportion of intravenous drug users (IVDUs) enrolled. In comparisons with the other groups of subjects, the IVDU s showed an increased risk of discontinuing treatment or being lost to follow-up (not significant, data not shown). Both these phenomena were equally distributed between treatment groups, indicating a similar influence in the two treatment arms. Other possible reasons for discontinuing treatment and loss to follow-up are difficult to ascertain, particularly for the latter. However, we believe that they may reflect, at least in part, reduced compliance in longterm administration of treatment, particularly with concurrent disease progression, symptoms of toxicity, and decline in CD4 cells. Conversely, the desire to seek other treatments did not represent a major reason, on the basis of available data and the fact that, during most of the study period, other antiretroviral therapies were not available.
No treatment differences were detected with respect to the patterns of new AIDS-defining events or reasons for death. A point of interest of our study was to investigate possible differences in the efficacy of the two drugs in preventing the development of AIDS dementia complex (ADC), because the superior (versus other drugs) ratio of zidovudine to cerebrospinal fluid or plasma may be associated with a better specific clinical efficacy with the drug in ADC [20] . In our study, 6 cases of ADC were observed as first AIDS-defining events, equally distributed between the 2 treatment groups (3 zidovudine, 3 ddI). These results do not suggest relevant differences in preventing this disease. However, it is difficult to draw definitive conclusions because of the low number of ADC events observed, which is possibly linked to the intermediate HIV disease status of our population. Further studies, of a population with more advanced HIV disease, could be helpful in clarifying this issue. ddI had a better effect than zidovudine on CD4 cell response and conversion from positive to negative for p24 antigen. The difference in CD4 cell responses between treatment groups was statistically significant in the first 6 months; the clear trend in favor of ddI, maintained for 18 months, suggested a more prolonged effect for ddI for patients still receiving treatment. Similar findings were observed comparing zidovudine and ddI monotherapies in the subgroup of zidovudine-naive patients of the ACTG 175 study [14] , in which ddI had a clearly better effect in terms of magnitude and duration of CD4 cell response. In the population of the ACTG 116A study [13] , who had more advanced disease, different results were observed. Zidovudine treatment was associated with a faster increase in CD4 cell counts at 2 weeks, and low-dosage ddI (500 mg/day) induced a slower decline in CD4 cell level compared with treatment in the other two arms (zidovudine and ddI, 750 mg/day). In the same study, p24 antigen changes did not show differences among treatment groups.
In our study, the occurrence of severe adverse events during treatment was generally moderate and similar between treatment groups, indicating overall acceptable tolerability of the two treatments. Zidovudine and ddI confirmed two distinct patterns of toxicity, in that hematologic toxicity was more frequent among zidovudine-treated subjects and pancreatic and neurologic toxicity was more commonly associated with ddl.
Despite the use of ddI in dosages slightly higher than those currently recommended (the 750 and 500 mg/day ddI in sachet formulation roughly corresponded, because ofthe different bioavailability, to 600 and 400 mg/day in tablet formulation, respectively), pancreatitis and severe peripheral neuropathy were uncommon events. The possible causes of this phenomenon may reflect the better tolerability ofnucleoside treatment before the diagnosis of AIDS, by the low number of concurrent medications used, and finally by the early discontinuation of treatment in the presence of asymptomatic hyperamylasemia or mild symptoms suggesting neuropathy.
In conclusion, in our trial zidovudine and ddI monotherapies resulted in similar clinical outcomes in untreated patients with mildly symptomatic HIV disease. Zidovudine was possibly more effective in short-term and ddI was more effective in long-term clinical outcome and on surrogate markers. Further studies would be necessary to confirm the hypothesis of a differential efficacy of the two drugs according to the level of immunosuppression and to investigate the possible biologic bases ofthis phenomenon. Although the results of the major trials comparing zidovudine and ddI in antiretroviral-naive patients have conflicted somewhat in terms of clinical outcome, some recently completed phase III trials have clearly indicated that zidovudine monotherapy is a therapeutic regimen characterized by suboptimal efficacy in terms of survival and progression to AIDS with respect to doublenucleoside regimens including ddI and zalcitabine [14, 21] ; consequently, zidovudine is no longer recommended as standard treatment [22] . Although ddI monotherapy can represent a more effective option, our results do not show an overall clear superiority of ddI over zidovudine.
Other combination regimens have recently been proved to profoundly inhibit HIV replication in previously untreated patients, with reduction of virus load to undetectable levels in a substantial proportion of cases. Methodologic issues make it difficult to prove, within controlled trials, the clinical superiority of early "aggressive" treatment. However, current evidence clearly indicates that antiretroviral treatment should aim to produce a maximal and durable suppression of viral replication to exert significant influence on the course ofHIV disease. Both monotherapies tested in this trial are considered suboptimal in terms of antiviral potency, and more powerful regimens based on a rationale combination ofnucleoside analogues, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors should be included in clinical practice.
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